GSK announces that it has become a founding partner of the Fleming Initiative, an innovative and collaborative approach led by Imperial College Healthcare NHS Trust and Imperial College London to combat antimicrobial resistance (AMR) worldwide.

AMR is recognized by the WHO as "an urgent threat to global public health".

The initiative aims to develop world-class scientific, technological, policy and behavioral expertise with clinical experience in a global network of centers to find, test and scale solutions to AMR.

GSK will invest £45m in the project, particularly around new technologies, such as AI, to better interpret complex scientific data, identify new opportunities to develop new therapeutic interventions and improve understanding of how drug-resistant infections are transmitted and can be prevented.


Copyright (c) 2024 CercleFinance.com. All rights reserved.